logo
The Step-By-Step Guide To Making Money From Selling Online Courses

The Step-By-Step Guide To Making Money From Selling Online Courses

Forbes09-04-2025
Kyle Scott
In 2019, Kyle Scott pitched a simple idea to celebrity real estate agent Ryan Serhant: turn his bestselling book Sell It Like Serhant into a course. Scott had never built a course before, but he understood something most creators miss—people don't buy information, they buy transformation. Two weeks after launch, the course had generated $500,000 in revenue. A few years later, the business was pulling in nearly $10 million a year from online education, coaching, and memberships.
Today, Scott is General Manager of High Growth Creators at Thinkific, where he helps creators and professionals turn their knowledge into real income. His message is clear: the tools have never been easier to use, but the business strategy still matters. 'The product isn't the hard part,' he told me. 'The hard part is structuring it, pricing it, creating demand for it. The hard part is building the business.'
If you're a content creator, subject-matter expert, or entrepreneur looking to generate meaningful revenue from online courses, this is the roadmap Scott recommends. It's not theory, it's the same strategy that turned one pitch into millions in sales.
The first and most important step isn't technical—it's mental. For many creators, the challenge is recognizing that they're not just making content. They're selling their expertise. That subtle shift changes everything.
Scott calls this the 'expert economy'—a growing segment of professionals who use content not to entertain, but to educate and convert. In his view, if you rely on social media for brand deals and AdSense revenue, you're in the creator economy. But if you use social media to drive attention to a product or service rooted in your expertise, you're in the expert economy. And it's the latter that offers long-term business potential.
This shift is particularly relevant in an AI-powered world. With tools like ChatGPT generating surface-level content at scale, those with real-world expertise stand out more than ever. 'You can't fake time and experience,' Scott explains. 'AI can give you buzzwords, but it can't do the work.'
One of the most common mistakes creators make is building a course around what they know, rather than what their audience wants to become. The distinction may seem subtle, but it makes all the difference.
People don't pay for content, they pay for outcomes. They want to lose weight, land a client, or get promoted. Creators who win in the course business understand that they're not selling information. They're selling a transformation.
Scott offers a simple framework: identify who the course is for, what it helps them do, and why that result matters to them. For example, a real estate course isn't just about selling homes, it's about making more money so agents can live the life they've always imagined. That emotional payoff is what drives purchase decisions.
Most new course creators underprice. Some fear charging too much. Others simply guess. But pricing is less about numbers and more about psychology.
Scott recommends launching with a high, medium, and low pricing tier. In his first course with real estate agent Ryan Serhant, they priced the base course at $499, bundled it with membership for a mid-tier option, and offered high-end coaching for nearly $10,000. Even if no one bought the premium tier (which they did, eight people purchased it in the first two weeks), it served as a signal of value.
The goal is to anchor your pricing and guide customers toward the middle. It's the same strategy used in SaaS, ecommerce, and car sales. As Scott puts it, 'Price only matters in the absence of value.'
A great course with no visibility will fail. That's why Scott spends so much time emphasizing the importance of marketing and positioning.
He argues that creators already have the hard part figured out, the content itself. The bigger challenge is building awareness. 'You could be the best spine surgeon in the world,' he says, 'but if no one knows about it, it doesn't matter.'
Creators should think of social media not as the business itself, but as their lead generation engine. Building an audience, sharing content, and telling your story are all prerequisites to launching a course.
Once you've built your audience and framed your transformation, the next step is to treat your course like a business. That means thinking in terms of funnels, sequences, and lifetime value.
Scott's approach involves clear pre-launch strategies: email waitlists, launch campaigns, ongoing nurture sequences, and value ladders that guide customers toward higher-priced products or services. Even if the course itself is $500, the business model is built on multiple revenue streams: coaching, memberships, templates, or speaking engagements.
That layered model helps balance customer acquisition costs (CAC) and lifetime value (LTV), the key metrics that separate sustainable course businesses from one-off successes. 'Three-to-one LTV to CAC is the gold standard,' Scott says. 'If you're hitting that, you can scale.'
Far from being a threat to online education, AI is becoming one of its biggest enablers. At Thinkific, AI now powers everything from sales page generation to course outlines, allowing creators to focus on what matters most, crafting a message and building trust.
For content planning, Scott favors Claude over ChatGPT and uses AI to write rough drafts for posts, emails, and even course copy. The trick, he says, is to treat it like a collaborator, not a replacement. 'AI gets you to v1. It saves time. But you still have to bring the perspective that only you have.'
Ironically, the final obstacle for most creators isn't tools or tactics, it's self-doubt.
Experts often underestimate themselves because they see complexity where others see clarity. Scott points to the 'Dunning-Kruger effect,' where true experts are more likely to question their competence simply because they know how much nuance exists.
But if you've spent years building a skill or career, you're likely far more qualified to teach than you think. 'To the kindergartner, the fifth grader is king,' Scott says. 'You only need to be a few steps ahead of someone to lead them.'
With digital tools, AI support, and platforms like Thinkific lowering the barrier to entry, there's never been a better moment to turn your expertise into income. The creator economy may be fueled by attention, but the expert economy is built on transformation. And it's only growing.
Whether you're a fitness coach, a lawyer, a marketer, or even a Harvard-trained spine surgeon, there's a market for your knowledge. But you have to treat it like a business. And the first step is just starting.
This article is based on an interview for The Business of Creators podcast.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Trending tickers: latest investor updates on Nvidia, Sarepta, Spotify, AstraZeneca and Greggs
Trending tickers: latest investor updates on Nvidia, Sarepta, Spotify, AstraZeneca and Greggs

Yahoo

time20 minutes ago

  • Yahoo

Trending tickers: latest investor updates on Nvidia, Sarepta, Spotify, AstraZeneca and Greggs

Nvidia (NVDA) Shares in the AI darling were trending in pre-market trading after finishing Monday's session almost 2% higher as retail investors remain bullish on the stock. The renewed optimism can be traced to growing expectations that the US may extend its trade truce with China by another 90 days. The original announcement has been a boon for Nvidia, whose fortunes have been closely tied to the evolving US-China trade relations. Earlier this month, in a pivotal move, the Trump administration reversed an earlier decision by lifting a ban imposed in April and allowing Nvidia to resume sales of its H20 GPUs to China. This decision, combined with reports of rising demand for Nvidia's AI chips, has provided support to the company's stock price. Amid increasing demand, Nvidia has reportedly placed an order for 300,000 H20 AI chips with Taiwan Semiconductor Manufacturing Company (TSM). This new order adds to Nvidia's existing inventory of between 600,000 and 700,000 chips. Read more: FTSE 100 LIVE: Markets higher as attention turns to slew of earnings reports Nvidia's H20 chip, which was designed specifically for the Chinese market, complies with US export restrictions and is less powerful than its more advanced AI models like the H100 or the Blackwell series. Sarepta (SRPT) Shares of Sarepta, a developer of gene therapies for rare diseases, jumped over 50% ahead of the US opening bell, after closing 16% higher on Monday, as the Food and Drug Administration (FDA) gave it the go-ahead to resume shipments of its key vaccine. The company's stock had taken a hit last week after the death of an 8-year-old boy in Brazil. In response, Sarepta paused shipments of Elevidys for ambulatory Duchenne's muscular dystrophy patients, allowing the FDA time to review safety data. However, after the FDA communicated its decision to lift the voluntary pause on shipments, Sarepta's stock saw a sharp rebound in pre-market rading. Jefferies analyst Andrew Tsai commented on the FDA's decision, saying it "significantly improves Elevidys' sales outlook in the near term." He added that "[Wall] Street will feel relieved about the situation." While the FDA's decision allows shipments to resume for ambulatory patients, the agency has indicated that Sarepta will need to provide additional safety study data before Elevidys can be used for older, non-ambulatory patients. The FDA said in a statement it "will continue to work with the sponsor regarding non-ambulatory patients, which remains subject to a voluntary hold, following two deaths." Spotify (SPOT) Shares in Spotify were down slightly on Tuesday as the music streaming giant prepares to report its second-quarter 2025 earnings before the US market opens. Analysts polled by Zacks expect Spotify to post $4.9bn in revenue for the quarter, reflecting a 20.3% increase year-on-year. Earnings are projected at $2.19 per share, representing a 53.2% jump from the same period a year earlier. Investor sentiment has been buoyed by a combination of strong subscription growth, price increases, and a streamlined cost structure. Shares have risen approximately 120% over the past 12 months, rebounding sharply from 2022 lows, as enthusiasm builds around Spotify's potential in AI-powered content recommendations and advertising innovation. Earlier this month, the stock reached an all-time high of $738.45, although it has since pulled back slightly. Read more: Barclays posts profit beat and announces £1bn share buyback Last week, Oppenheimer analyst Jason Helfstein upgraded his rating on Spotify from "perform" to "outperform", assigning a price target of $800. 'We believe that SPOT will benefit from the secular tailwind of growing digital audio streaming adoption and that the company's subscription economics are better than most believe,' Helfstein wrote in a note to clients. AstraZeneca (AZN.L) Shares in AstraZeneca rose in London trading on Tuesday after the UK's largest listed company by market value reported stronger-than-expected second-quarter earnings and reaffirmed its full-year outlook. The pharmaceutical group posted an 11% rise in revenues to $14.46bn for the three months to the end of June, surpassing analyst expectations of $14.15bn, according to a company-compiled consensus. Core earnings per share came in at $2.17, just above forecasts of $2.16. "Our strong momentum in revenue growth continued through the first half of the year and the delivery from our broad and diverse pipeline has been excellent," CEO Pascal Soriot said in a statement. Pre-tax profit for the period rose to $3.1bn from $2.4bn a year earlier, as AstraZeneca saw strong performance across key therapeutic areas, including an 18% rise in oncology sales. The FTSE 100 (^FTSE) drugmaker, which derives 44% of its revenue from the US, is also ramping up investment in the country. Last week, it pledged to invest $50bn in the US by 2030, joining a wave of multinational pharmaceutical firms positioning themselves ahead of the potential imposition of tariffs on the sector by US president Donald Trump. Sheena Berry, healthcare analyst at Quilter Cheviot, said: 'AstraZeneca continues to deliver strong growth, with its second quarter results showing solid rises in product sales, up 10% overall. "This was primarily driven by 18% growth seen from the oncology portfolio, which has done well as a result of key drugs such as Imfinzi, Tagrisso and Enhertu. The group shows no sign of slowing down either with research and development spend increasing 18% in the quarter. Read more: Stocks to watch this week: Microsoft, Apple, Shell, AstraZeneca and HSBC 'For now, 2025's guidance has been reiterated with sales expected to increase by high single-digits and core earnings to grow by low double-digits. This remains a catalyst-rich period for the group with multiple positive phase III readouts and drug approvals in 2025 to date. "The main pipeline update included in the results is the Avanzar lung cancer trial readout, which is now expected in the first half of 2026, rather than later this year as was expected. However, the long-term outlook remains attractive with the group making progress towards its target of $80bn in total revenue by 2030.' Greggs (GRG.L) Shares were down by 3% as Greggs reported a 14% drop in pre-tax profit for the first half of the year, as winter storms and summer heatwaves kept customers away from its high street shops, adding to an already challenging consumer environment. The bakery chain, known for its sausage rolls and steak bakes, said profits fell to £63.5m in the six months to the end of June, down from £74.1m a year earlier. While total sales rose 7% to £1.03bn, the increase was not enough to offset a decline in margins and footfall. Company-managed shop like-for-like sales rose 2.6%, while franchised locations grew 4.8%. Greggs, which operates more than 2,600 stores across the UK, said the decline in profits 'reflected challenging market footfall and the phasing of cost headwinds that have particularly impacted the first half of the year.' 'These challenges were compounded by heavy snow and strong winds in January and unusually hot weather in June, which had a material impact on consumer behaviour and lowered like-for-like sales,' the company said. More than 200 shops in Scotland and Wales were temporarily closed during Storm Éowyn in late January, when a rare red warning was issued due to hurricane-force winds, heavy rain, and snow. Cost inflation was also a factor, with overall cost pressures running at 5.4% in the first half. Full-year cost inflation is expected to be around 6%. Greggs spent £3m on expanding manufacturing, logistics, and technology capabilities, and completed 108 shop refurbishments, up from 81 a year earlier. Chief executive Roisin Currie described the first half as a 'challenging market' with weak consumer confidence. 'People are saving, not spending,' she said. The interim dividend was held steady at 19p. While full-year sales are expected to remain resilient, profits are forecast to come in 'modestly below the level achieved in 2024.' Mark Crouch, market analyst at eToro, said: 'Greggs' 14% drop in first-half profit caps a bitter 10 months for the UKs favourite baker. "Management blames hot weather for weaker sales, but that doesn't account for a 50% collapse in market value. The more plausible culprit is the timing of Greggs expansion strategy, stretching margins, just as the consumer picture turns more fragile. 'Greggs has long been a reliable read on the UK high street. Its sudden stumble suggests consumers may not just be cooling on sausage rolls, but that appetite across the high street may be waning more broadly. "With inflation easing and real wages recovering, the macro backdrop should, in theory, be supportive. That it isn't showing up in Greggs' numbers, is a red flag. 'Greggs' brand still holds a strong place in the market, but scale isn't helping if margins and volumes can't keep up. The pressure is now squarely on management to regain the initiative, and not just blame it on the weather.'

Trending tickers: latest investor updates on Nvidia, Sarepta, Spotify, AstraZeneca and Greggs
Trending tickers: latest investor updates on Nvidia, Sarepta, Spotify, AstraZeneca and Greggs

Yahoo

time27 minutes ago

  • Yahoo

Trending tickers: latest investor updates on Nvidia, Sarepta, Spotify, AstraZeneca and Greggs

Nvidia (NVDA) Shares in the AI darling were trending in pre-market trading after finishing Monday's session almost 2% higher as retail investors remain bullish on the stock. The renewed optimism can be traced to growing expectations that the US may extend its trade truce with China by another 90 days. The original announcement has been a boon for Nvidia, whose fortunes have been closely tied to the evolving US-China trade relations. Earlier this month, in a pivotal move, the Trump administration reversed an earlier decision by lifting a ban imposed in April and allowing Nvidia to resume sales of its H20 GPUs to China. This decision, combined with reports of rising demand for Nvidia's AI chips, has provided support to the company's stock price. Amid increasing demand, Nvidia has reportedly placed an order for 300,000 H20 AI chips with Taiwan Semiconductor Manufacturing Company (TSM). This new order adds to Nvidia's existing inventory of between 600,000 and 700,000 chips. Read more: FTSE 100 LIVE: Markets higher as attention turns to slew of earnings reports Nvidia's H20 chip, which was designed specifically for the Chinese market, complies with US export restrictions and is less powerful than its more advanced AI models like the H100 or the Blackwell series. Sarepta (SRPT) Shares of Sarepta, a developer of gene therapies for rare diseases, jumped over 50% ahead of the US opening bell, after closing 16% higher on Monday, as the Food and Drug Administration (FDA) gave it the go-ahead to resume shipments of its key vaccine. The company's stock had taken a hit last week after the death of an 8-year-old boy in Brazil. In response, Sarepta paused shipments of Elevidys for ambulatory Duchenne's muscular dystrophy patients, allowing the FDA time to review safety data. However, after the FDA communicated its decision to lift the voluntary pause on shipments, Sarepta's stock saw a sharp rebound in pre-market rading. Jefferies analyst Andrew Tsai commented on the FDA's decision, saying it "significantly improves Elevidys' sales outlook in the near term." He added that "[Wall] Street will feel relieved about the situation." While the FDA's decision allows shipments to resume for ambulatory patients, the agency has indicated that Sarepta will need to provide additional safety study data before Elevidys can be used for older, non-ambulatory patients. The FDA said in a statement it "will continue to work with the sponsor regarding non-ambulatory patients, which remains subject to a voluntary hold, following two deaths." Spotify (SPOT) Shares in Spotify were down slightly on Tuesday as the music streaming giant prepares to report its second-quarter 2025 earnings before the US market opens. Analysts polled by Zacks expect Spotify to post $4.9bn in revenue for the quarter, reflecting a 20.3% increase year-on-year. Earnings are projected at $2.19 per share, representing a 53.2% jump from the same period a year earlier. Investor sentiment has been buoyed by a combination of strong subscription growth, price increases, and a streamlined cost structure. Shares have risen approximately 120% over the past 12 months, rebounding sharply from 2022 lows, as enthusiasm builds around Spotify's potential in AI-powered content recommendations and advertising innovation. Earlier this month, the stock reached an all-time high of $738.45, although it has since pulled back slightly. Read more: Barclays posts profit beat and announces £1bn share buyback Last week, Oppenheimer analyst Jason Helfstein upgraded his rating on Spotify from "perform" to "outperform", assigning a price target of $800. 'We believe that SPOT will benefit from the secular tailwind of growing digital audio streaming adoption and that the company's subscription economics are better than most believe,' Helfstein wrote in a note to clients. AstraZeneca (AZN.L) Shares in AstraZeneca rose in London trading on Tuesday after the UK's largest listed company by market value reported stronger-than-expected second-quarter earnings and reaffirmed its full-year outlook. The pharmaceutical group posted an 11% rise in revenues to $14.46bn for the three months to the end of June, surpassing analyst expectations of $14.15bn, according to a company-compiled consensus. Core earnings per share came in at $2.17, just above forecasts of $2.16. "Our strong momentum in revenue growth continued through the first half of the year and the delivery from our broad and diverse pipeline has been excellent," CEO Pascal Soriot said in a statement. Pre-tax profit for the period rose to $3.1bn from $2.4bn a year earlier, as AstraZeneca saw strong performance across key therapeutic areas, including an 18% rise in oncology sales. The FTSE 100 (^FTSE) drugmaker, which derives 44% of its revenue from the US, is also ramping up investment in the country. Last week, it pledged to invest $50bn in the US by 2030, joining a wave of multinational pharmaceutical firms positioning themselves ahead of the potential imposition of tariffs on the sector by US president Donald Trump. Sheena Berry, healthcare analyst at Quilter Cheviot, said: 'AstraZeneca continues to deliver strong growth, with its second quarter results showing solid rises in product sales, up 10% overall. "This was primarily driven by 18% growth seen from the oncology portfolio, which has done well as a result of key drugs such as Imfinzi, Tagrisso and Enhertu. The group shows no sign of slowing down either with research and development spend increasing 18% in the quarter. Read more: Stocks to watch this week: Microsoft, Apple, Shell, AstraZeneca and HSBC 'For now, 2025's guidance has been reiterated with sales expected to increase by high single-digits and core earnings to grow by low double-digits. This remains a catalyst-rich period for the group with multiple positive phase III readouts and drug approvals in 2025 to date. "The main pipeline update included in the results is the Avanzar lung cancer trial readout, which is now expected in the first half of 2026, rather than later this year as was expected. However, the long-term outlook remains attractive with the group making progress towards its target of $80bn in total revenue by 2030.' Greggs (GRG.L) Shares were down by 3% as Greggs reported a 14% drop in pre-tax profit for the first half of the year, as winter storms and summer heatwaves kept customers away from its high street shops, adding to an already challenging consumer environment. The bakery chain, known for its sausage rolls and steak bakes, said profits fell to £63.5m in the six months to the end of June, down from £74.1m a year earlier. While total sales rose 7% to £1.03bn, the increase was not enough to offset a decline in margins and footfall. Company-managed shop like-for-like sales rose 2.6%, while franchised locations grew 4.8%. Greggs, which operates more than 2,600 stores across the UK, said the decline in profits 'reflected challenging market footfall and the phasing of cost headwinds that have particularly impacted the first half of the year.' 'These challenges were compounded by heavy snow and strong winds in January and unusually hot weather in June, which had a material impact on consumer behaviour and lowered like-for-like sales,' the company said. More than 200 shops in Scotland and Wales were temporarily closed during Storm Éowyn in late January, when a rare red warning was issued due to hurricane-force winds, heavy rain, and snow. Cost inflation was also a factor, with overall cost pressures running at 5.4% in the first half. Full-year cost inflation is expected to be around 6%. Greggs spent £3m on expanding manufacturing, logistics, and technology capabilities, and completed 108 shop refurbishments, up from 81 a year earlier. Chief executive Roisin Currie described the first half as a 'challenging market' with weak consumer confidence. 'People are saving, not spending,' she said. The interim dividend was held steady at 19p. While full-year sales are expected to remain resilient, profits are forecast to come in 'modestly below the level achieved in 2024.' Mark Crouch, market analyst at eToro, said: 'Greggs' 14% drop in first-half profit caps a bitter 10 months for the UKs favourite baker. "Management blames hot weather for weaker sales, but that doesn't account for a 50% collapse in market value. The more plausible culprit is the timing of Greggs expansion strategy, stretching margins, just as the consumer picture turns more fragile. 'Greggs has long been a reliable read on the UK high street. Its sudden stumble suggests consumers may not just be cooling on sausage rolls, but that appetite across the high street may be waning more broadly. "With inflation easing and real wages recovering, the macro backdrop should, in theory, be supportive. That it isn't showing up in Greggs' numbers, is a red flag. 'Greggs' brand still holds a strong place in the market, but scale isn't helping if margins and volumes can't keep up. The pressure is now squarely on management to regain the initiative, and not just blame it on the weather.'

Dubai Chamber of Digital Economy Launches The Entrepreneur's AI Playbook
Dubai Chamber of Digital Economy Launches The Entrepreneur's AI Playbook

Entrepreneur

timean hour ago

  • Entrepreneur

Dubai Chamber of Digital Economy Launches The Entrepreneur's AI Playbook

The playbook offers valuable guidance on the artificial intelligence tools available to support every stage of developing entrepreneurial projects. You're reading Entrepreneur Middle East, an international franchise of Entrepreneur Media. Dubai Chamber of Digital Economy, one of the three chambers operating under the umbrella of Dubai Chambers, has launched 'The Entrepreneur's AI Playbook' to raise awareness about the artificial intelligence tools and applications entrepreneurs can leverage to successfully launch, manage, and scale their businesses. The guide was developed as part of the 'Create Apps in Dubai' initiative launched by His Highness Sheikh Hamdan bin Mohammed bin Rashid Al Maktoum, Crown Prince of Dubai, Deputy Prime Minister and Minister of Defence of the UAE, and Chairman of The Executive Council of Dubai. 'Create Apps in Dubai' seeks to train and upskill 1,000 UAE nationals, strengthen digital capabilities, and triple the number of app developers in Dubai, as well as support the launch of 100 new homegrown mobile application projects. The initiative also includes the 'Create Apps Championship,' which seeks to reinforce Dubai's leadership in smart application development, attract global talent, and encourage entrepreneurs to present their ideas for innovative mobile apps. The Entrepreneur's AI Playbook offers practical guidance on artificial intelligence tools that can be used at every stage of developing entrepreneurial ventures and startups. This includes the setup phase, covering naming and brand identity, followed by developing value propositions, business models, and digital products and services. The guide also addresses the operational phase, including customer acquisition, fulfilment, billing, and customer support. The guide highlights Dubai's commitment to building a world-class AI ecosystem, which is reflected in several strategic initiatives and events. These include the AI Retreat, the Dubai Universal Blueprint for AI, the appointment of Chief AI Officers across government entities, and AI Week in Dubai schools, together with programmes designed to empower entrepreneurs to harness advanced AI technologies across diverse sectors. The Entrepreneur's AI Playbook is available for download on the Dubai Chamber of Digital Economy website here.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store